Skip to main content
. 2016 May 4;7(24):36767–36782. doi: 10.18632/oncotarget.9168

Figure 5. Sorafenib downregulates the Raf/MEK/ERK signaling pathway and concurrent treatment with DCP antagonizes the Sorafenib-mediated downregulation.

Figure 5

A-C. Western blot analysis was used to evaluate the expression of Raf, MEK and ERK kinases in HLE cells treated with Sorafenib (A), DCP (B), and Sorafenib in the presence of DCP (C), D. The expression levels of Raf, MEK and ERK in HLE xenografts. Gels were run under the same experimental conditions. The cropping lines in the figure represent full-length gels. Levels of proteins were compared to the vehicle control, which was set to 100%. Sorafenib inhibited the expressions of Raf, MEK and ERK kinases, whereas the levels of these kinases were stimulated by DCP (D, right panel). The bars indicate means ± S.D (n = 3). *p < 0.05, **p < 0.01 vs. the vehicle control.